Plain-English translation of NCT06691685 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called ESO-T01 for people with multiple myeloma that has returned or stopped responding to standard medicines. ESO-T01 is a type of gene therapy that works by modifying your immune cells to fight cancer cells. The study will carefully monitor your safety and how well this medication works, starting with smaller doses and gradually increasing them.
Multiple myeloma is a blood cancer that often comes back or becomes resistant to existing treatments, leaving patients with limited options. This medication represents a new approach using your own immune system to target cancer cells, and researchers want to see if it can help people who have run out of other choices.
You will receive ESO-T01 through an IV infusion, and your body will then produce the cancer-fighting cells directly. You'll have regular clinic visits for blood tests, physical exams, and scans to monitor how you're responding and check for any side effects. The study uses a dose-escalation design, meaning early participants receive lower doses and later participants receive higher doses as safety is confirmed; most of your follow-up care will happen over the first few months after treatment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators
Shenzhen Pregene Biopharma Co., Ltd.
Enrollment target
~24 participants
Started
November 2024
Primary completion
November 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.